

Yao Chi Chuang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3098384/publications.pdf>

Version: 2024-02-01

140
papers

4,155
citations

109137

35
h-index

138251

58
g-index

142
all docs

142
docs citations

142
times ranked

2930
citing authors

#	ARTICLE	IF	CITATIONS
1	Impacts of nocturia on quality of life, mental health, work limitation, and health care seeking in China, Taiwan and South Korea (LUTS Asia): Results from a cross-sectional, population-based study. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 285-293.	0.8	10
2	Low energy shock wave therapy attenuates mitochondrial dysfunction and improves bladder function in HCl induced cystitis in rats. <i>Biomedical Journal</i> , 2022, 45, 482-490.	1.4	11
3	Prevalence and impacts of male urinary incontinence on quality of life, mental health, work limitation, and health care seeking in China, Taiwan, and South Korea (LUTS Asia): Results from a cross-sectional, population-based study. <i>Investigative and Clinical Urology</i> , 2022, 63, 71.	1.0	5
4	Response to a Letter to Editor for article "Impacts of nocturia on quality of life, mental health, work limitation, and health care seeking in China, Taiwan and South Korea (LUTS Asia): Results from a cross-sectional, population-based study" <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1016-1016.	0.8	0
5	New Frontiers of Extracorporeal Shock Wave Medicine in Urology from Bench to Clinical Studies. <i>Biomedicines</i> , 2022, 10, 675.	1.4	12
6	Effects of TORS-OSA Surgery on Lower Urinary Tract Symptoms, Overactive Bladder Symptoms, and Nocturia in Male Patients with Obstructive Sleep Apnea/Hypopnea Syndrome. <i>Nature and Science of Sleep</i> , 2022, Volume 14, 547-556.	1.4	2
7	The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 850874.	1.3	2
8	Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders" A cohort study. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2101-2108.	0.8	1
9	Molecular Effects of Low-Intensity Shock Wave Therapy on L6 Dorsal Root Ganglion/Spinal Cord and Blood Oxygenation Level-Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Changes in Capsaicin-Induced Prostatitis Rat Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4716.	1.8	4
10	A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 108-117.	0.6	3
11	Lifestyle and behavioral modifications made by patients with interstitial cystitis. <i>Scientific Reports</i> , 2021, 11, 3055.	1.6	5
12	The Prognostic Impact of Tumor Architecture for Upper Urinary Tract Urothelial Carcinoma: A Propensity Score-Weighted Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 613696.	1.3	6
13	Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. <i>Scientific Reports</i> , 2021, 11, 8202.	1.6	12
14	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021, 11, 7558.	1.6	10
15	Comparative safety review of current pharmacological treatments for interstitial cystitis/ bladder pain syndrome. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1049-1059.	1.0	4
16	Interstitial cystitis/bladder pain syndrome patient is associated with subsequent increased risks of outpatient visits and hospitalizations: A population-based study. <i>PLoS ONE</i> , 2021, 16, e0256800.	1.1	4
17	Extracorporeal Shock Wave Enhances the Cisplatin Efficacy by Improving Tissue Infiltration and Cellular Uptake in an Upper Urinary Tract Cancer Animal and Human-Derived Organoid Model. <i>Cancers</i> , 2021, 13, 4558.	1.7	5
18	COVID-19 pandemic impact on urology residencies in Asia "An observational study. <i>Surgical Practice</i> , 2021, 25, 10-15.	0.1	2

#	ARTICLE	IF	CITATIONS
19	Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwanâ€”A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study). <i>Toxins</i> , 2021, 13, 911.	1.5	4
20	Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 55-59.	0.6	4
21	The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS. <i>International Urology and Nephrology</i> , 2020, 52, 815-820.	0.6	6
22	Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. <i>International Journal of Clinical Practice</i> , 2020, 74, e13537.	0.8	0
23	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndromeâ€”A prospective, multicenter, randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1505-1514.	0.8	27
24	The prevalence of urinary incontinence in men and women aged 40â€”years or over in China, Taiwan and South Korea: A cross-sectional, prevalence-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 223-234.	0.6	10
25	Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwanâ€”Japan UTUC Collaboration Cohort. <i>International Journal of Urology</i> , 2020, 27, 327-332.	0.5	16
26	Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder. <i>Toxins</i> , 2020, 12, 75.	1.5	10
27	New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave. <i>International Neurourology Journal</i> , 2020, 24, 211-221.	0.5	20
28	Reply to the Commentary on â€œNew Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Waveâ€”. <i>International Neurourology Journal</i> , 2020, 24, 389-390.	0.5	0
29	Risks of interstitial cystitis among patients with systemic lupus erythematosus: A population-based cohort study. <i>International Journal of Urology</i> , 2019, 26, 897-902.	0.5	20
30	Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome. <i>Toxins</i> , 2019, 11, 586.	1.5	3
31	Baâ€”Weiâ€”Dieâ€”Huangâ€”Wan (Hachimiâ€”jioâ€”gan) can ameliorate ketamine-induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model. <i>Neurourology and Urodynamics</i> , 2019, 38, 2159-2169.	0.8	13
32	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4777.	1.8	18
33	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. <i>International Urology and Nephrology</i> , 2019, 51, 617-626.	0.6	8
34	Prevalence of overactive bladder in <sc>C</sc>hina, <sc>T</sc>aiwan and <sc>S</sc>outh <sc>K</sc>orea: <sc>R</sc>esults from a cross-sectional, population-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 48-55.	0.6	74
35	Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan, and South Korea: Subgroup analysis of a cross-sectional, population-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, O78-O84.	0.6	14
36	The prevalence and bother of lower urinary tract symptoms in men and women aged 40 years or over in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 170-178.	0.8	24

#	ARTICLE	IF	CITATIONS
37	Potential Orphan Drug Therapy of Intravesical Liposomal Onabotulinumtoxin-A for Ketamine-Induced Cystitis by Mucosal Protection and Anti-inflammation in a Rat Model. <i>Scientific Reports</i> , 2018, 8, 5795.	1.6	19
38	Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 3-11.	0.6	32
39	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. <i>Neurourology and Urodynamics</i> , 2018, 37, 708-715.	0.8	14
40	Extracorporeal Shockwave Therapy Assisted Intravesical Drug Delivery. <i>Translational Research in Biomedicine</i> , 2018, , 117-126.	0.4	1
41	The prevalence and risk factors of nocturia in China, South Korea, and Taiwan: results from a cross-sectional, population-based study. <i>World Journal of Urology</i> , 2018, 36, 1853-1862.	1.2	22
42	Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence. <i>International Journal of Urology</i> , 2018, 25, 615-620.	0.5	10
43	Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	10
44	Efficacy and persistence of low-dose mirabegron (25Åmg) in patients with overactive bladder: analysis in a real-world urological practice. <i>International Urology and Nephrology</i> , 2018, 50, 1219-1226.	0.6	7
45	A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome. <i>Journal of Urology</i> , 2017, 198, 376-382.	0.2	56
46	Effects of low energy shock wave therapy on inflammatory moleculars, bladder pain, and bladder function in a rat cystitis model. <i>Neurourology and Urodynamics</i> , 2017, 36, 1440-1447.	0.8	39
47	Potential applications of low-energy shock waves in functional urology. <i>International Journal of Urology</i> , 2017, 24, 573-581.	0.5	33
48	Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study. <i>Advances in Therapy</i> , 2017, 34, 1953-1965.	1.3	82
49	Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study. <i>BMC Urology</i> , 2017, 17, 108.	0.6	31
50	Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasiaâ€”A Spotlight in Reality. <i>Toxins</i> , 2016, 8, 126.	1.5	18
51	Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 458-463.	0.8	4
52	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F548-F554.	1.3	24
53	Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus. <i>International Urology and Nephrology</i> , 2016, 48, 1209-1214.	0.6	16
54	The prevalence and predictors of androgen deficiency in Taiwanese men with lower urinary tract symptoms. <i>Urological Science</i> , 2016, 27, 83-85.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. <i>International Urology and Nephrology</i> , 2016, 48, 993-999.	0.6	32
56	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. <i>Journal of Urology</i> , 2016, 196, 599-608.	0.2	39
57	Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder. <i>Journal of Ethnopharmacology</i> , 2016, 184, 1-9.	2.0	22
58	Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 521-529.	1.9	22
59	Diabetes and Other Neurogenic Underactive Bladder Conditions. , 2016, , 163-176.		0
60	Underactive Bladder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 523-533.	1.0	18
61	Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. <i>International Urology and Nephrology</i> , 2015, 47, 275-281.	0.6	54
62	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. <i>Urology</i> , 2015, 85, 1284-1290.	0.5	8
63	Role of liposome in treatment of overactive bladder and interstitial cystitis. <i>Urological Science</i> , 2015, 26, 3-6.	0.2	9
64	Predictors of Prostate-Specific Antigen Biochemical Recurrence in Patients Undergoing Primary Whole-Gland Prostate Cryoablation. <i>Annals of Surgical Oncology</i> , 2015, 22, 1612-1617.	0.7	10
65	Functional and Molecular Characterization of Hyposensitive Underactive Bladder Tissue and Urine in Streptozotocin-Induced Diabetic Rat. <i>PLoS ONE</i> , 2014, 9, e102644.	1.1	33
66	Non-Obstructive bladder conditions in female Taiwanese patients with interstitial cystitis/hypersensitive bladder syndrome. <i>International Journal of Urology</i> , 2014, 21, 805-809.	0.5	20
67	Oncological impact of endoscopic bladder cuff management during nephroureterectomy varies according to upper urinary tract tumor location. <i>International Journal of Urology</i> , 2014, 21, 366-369.	0.5	11
68	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. <i>European Urology</i> , 2014, 65, 1117-1124.	0.9	100
69	Association of inflammaging (inflammation+aging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014, 46, 871-877.	0.6	45
70	Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. <i>International Urology and Nephrology</i> , 2014, 46, 921-926.	0.6	26
71	Mechanism of action of onabotulinumtoxinA on lower urinary tract dysfunction. <i>Tzu Chi Medical Journal</i> , 2014, 26, 1-4.	0.4	2
72	Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome. <i>BJU International</i> , 2014, 113, E144-9.	1.3	48

#	ARTICLE	IF	CITATIONS
73	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. <i>Journal of Urology</i> , 2014, 192, 1743-1749.	0.2	88
74	Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes. <i>International Urology and Nephrology</i> , 2014, 46, 1269-1275.	0.6	32
75	The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 506-512.	0.8	19
76	Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. <i>Current Bladder Dysfunction Reports</i> , 2013, 8, 174-179.	0.2	2
77	Intravesical drug delivery for dysfunctional bladder. <i>International Journal of Urology</i> , 2013, 20, 552-562.	0.5	48
78	Diagnostic Ureteroscopy Independently Correlates with Intravesical Recurrence after Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 3121-3126.	0.7	66
79	Can high-dose-rate brachytherapy prevent the major genitourinary complication better than external beam radiation alone for patients with previous transurethral resection of prostate?. <i>International Urology and Nephrology</i> , 2013, 45, 113-119.	0.6	10
80	Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 276-282.	0.8	27
81	Medical diseases affecting lower urinary tract function. <i>Urological Science</i> , 2013, 24, 41-45.	0.2	13
82	The Prevalence and Predictors of Androgen Deficiency in Taiwanese Men With Type 2 Diabetes. <i>Urology</i> , 2013, 82, 124-129.	0.5	18
83	Development of Potential Orphan Drug Therapy of Intravesical Liposomal Tacrolimus for Hemorrhagic Cystitis Due to Increased Local Drug Exposure. <i>Journal of Urology</i> , 2013, 189, 1553-1558.	0.2	25
84	Severity of hydronephrosis correlates with tumour invasiveness and urinary bladder recurrence of ureteric cancer. <i>BJU International</i> , 2013, 112, 489-494.	1.3	7
85	OnabotulinumtoxinA Has No Effects on Growth of LNCaP and PC3 Human Prostate Cancer Cells. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2013, 5, 168-172.	0.6	4
86	Intravesical therapy for lower urinary tract symptoms. <i>Urological Science</i> , 2012, 23, 70-77.	0.2	15
87	High-intensity diode laser in combination with bipolar transurethral resection of the prostate: A new strategy for the treatment of large prostates (>80ml). <i>Lasers in Surgery and Medicine</i> , 2012, 44, 699-704.	1.1	19
88	Sensory Dysfunction of Bladder Mucosa and Bladder Oversensitivity in a Rat Model of Metabolic Syndrome. <i>PLoS ONE</i> , 2012, 7, e45578.	1.1	39
89	Albuminuria is an Independent Risk Factor of Erectile Dysfunction in Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2012, 9, 1055-1064.	0.3	31
90	The Presence of Overactive Bladder Wet Increased the Risk and Severity of Erectile Dysfunction in Men with Type 2 Diabetes. <i>Journal of Sexual Medicine</i> , 2012, 9, 1913-1922.	0.3	23

#	ARTICLE	IF	CITATIONS
91	Pathophysiology of Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 48-55.	0.6	49
92	Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E ₂ -induced bladder overactivity in rats. BJU International, 2012, 110, 1558-1564.	1.3	17
93	1954 AGE ASSOCIATED CHANGES IN URINARY PROTEOME OF OAB PATIENTS. Journal of Urology, 2011, 185, .	0.2	2
94	1370 URINE ANALYSIS OF CONFIRMED UTI PATIENTS REVEAL HIGHER LEVELS OF CXC CHEMOKINES COMPARED TO PATIENTS WITH LUTS WITHOUT UTI. Journal of Urology, 2011, 185, .	0.2	1
95	Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome. Kaohsiung Journal of Medical Sciences, 2011, 27, 437-440.	0.8	27
96	Prevalence of Overactive Bladder and Associated Risk Factors in 1359 Patients With Type 2 Diabetes. Urology, 2011, 78, 1040-1045.	0.5	93
97	Pathophysiological Studies of Overactive Bladder and Bladder Motor Dysfunction in a Rat Model of Metabolic Syndrome. Journal of Urology, 2011, 186, 318-325.	0.2	36
98	TWISTING MANEUVER FOR SUTURELESS VITRECTOMY TROCAR INSERTION TO REDUCE INTRAOPERATIVE INTRAOCULAR PRESSURE RISE. Retina, 2011, 31, 887-892.	1.0	7
99	Application of resonance metallic stents for ureteral obstruction. BJU International, 2011, 108, 428-432.	1.3	71
100	Efficacy and safety of photoselective vaporization of the prostate in patients with prostatic obstruction induced by advanced prostate cancer. Asian Journal of Surgery, 2011, 34, 135-139.	0.2	0
101	Long-term outcome of radical cystectomy in ESDR patients with bladder urothelial carcinoma. International Urology and Nephrology, 2011, 43, 1067-1071.	0.6	17
102	Development of cellular therapy for the treatment of stress urinary incontinence. International Urogynecology Journal, 2011, 22, 1075-1083.	0.7	40
103	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourology and Urodynamics, 2011, 30, 421-427.	0.8	36
104	Is Hand-Assisted Retroperitoneoscopic Nephroureterectomy Better Than Transurethral Bladder Cuff Incision-Assisted Nephroureterectomy?. Journal of Endourology, 2011, 25, 1307-1313.	1.1	11
105	GreenLight HPS laser 120W versus diode laser 200W vaporization of the prostate: Comparative clinical experience. Lasers in Surgery and Medicine, 2010, 42, 624-629.	1.1	60
106	Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU International, 2010, 105, 668-672.	1.3	25
107	Expression of E-series prostaglandin (EP) receptors and urodynamic effects of an EP ₄ receptor antagonist on cyclophosphamide-induced overactive bladder in rats. BJU International, 2010, 106, 1782-1787.	1.3	22
108	Botulinum toxin for the lower urinary tract. BJU International, 2010, 105, 1046-1058.	1.3	27

#	ARTICLE	IF	CITATIONS
109	Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. <i>Urological Science</i> , 2010, 21, 132-136.	0.2	34
110	Preliminary Results of Prostate Vaporization in the Treatment of Benign Prostatic Hyperplasia by Using a 200-W High-intensity Diode Laser. <i>Urology</i> , 2010, 75, 658-663.	0.5	46
111	1590 DISCRIMINATION OF OAB FROM IC/PBS BY MULTIVARIATE DATA MODELING OF URINARY PROTEINS. <i>Journal of Urology</i> , 2010, 183, .	0.2	1
112	Application of Botulinum Toxin in the Prostate. , 2009, , 273-282.e1.		0
113	Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats. <i>European Urology</i> , 2009, 56, 159-167.	0.9	84
114	Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. <i>BJU International</i> , 2009, 104, 1620-1623.	1.3	15
115	Bladder Botulinum Toxin. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S22.	0.6	1
116	Localized Effects of Antimuscarinics in the Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S56.	0.6	0
117	Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S90.	0.6	2
118	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. <i>Journal of Urology</i> , 2009, 182, 786-792.	0.2	118
119	Intravesical Liposome Versus Oral Pentosan Polysulfate for Interstitial Cystitis/Painful Bladder Syndrome. <i>Journal of Urology</i> , 2009, 182, 1393-1400.	0.2	88
120	Treatment of painful bladder syndrome and pelvic organ prolapse: highlights of the 4th international consultation on incontinence, July 5-8, 2008, Paris, France. <i>Reviews in Urology</i> , 2009, 11, 28-32.	0.9	0
121	Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. <i>International Urogynecology Journal</i> , 2008, 19, 1353-1357.	0.7	33
122	Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. <i>BJU International</i> , 2008, 102, 704-706.	1.3	50
123	Intraprostatic Botulinum Toxin A Injection Inhibits Cyclooxygenase-2 Expression and Suppresses Prostatic Pain on Capsaicin Induced Prostatitis Model in Rat. <i>Journal of Urology</i> , 2008, 180, 742-748.	0.2	84
124	EFFECTS OF BOTULINUM TOXIN A ON SNAP25 LEVEL AND BLADDER FUNCTION IN A CYCLOPHOSPHAMIDE INDUCED CYSTITIS MODEL IN RATS. <i>Journal of Urology</i> , 2008, 179, 61-61.	0.2	2
125	Intraprostatic Capsaicin Injection as a Novel Model for Nonbacterial Prostatitis and Effects of Botulinum Toxin A. <i>European Urology</i> , 2007, 51, 1119-1127.	0.9	67
126	The Application of Botulinum Toxin in the Prostate. <i>Journal of Urology</i> , 2006, 176, 2375-2382.	0.2	80

#	ARTICLE	IF	CITATIONS
127	Novel Action of Botulinum Toxin on the Stromal and Epithelial Components of the Prostate Gland. <i>Journal of Urology</i> , 2006, 175, 1158-1163.	0.2	141
128	Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. <i>BMC Urology</i> , 2006, 6, 12.	0.6	80
129	The potential and promise of using botulinum toxin in the prostate gland. <i>BJU International</i> , 2006, 98, 28-32.	1.3	28
130	Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. <i>BJU International</i> , 2006, 98, 1033-1037.	1.3	102
131	Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. <i>Urology</i> , 2005, 65, 804-810.	0.5	25
132	Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. <i>Urology</i> , 2005, 66, 775-779.	0.5	114
133	High-dose rate iridium-192 brachytherapy and external beam radiation therapy for prostate cancer with or without androgen ablation. <i>International Journal of Urology</i> , 2004, 11, 152-158.	0.5	17
134	INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS. <i>Journal of Urology</i> , 2004, 172, 1529-1532.	0.2	242
135	Gene Therapy for Bladder Pain With Gene Gun Particle Encoding Pro-Opiomelanocortin cDNA. <i>Journal of Urology</i> , 2003, 170, 2044-2048.	0.2	32
136	Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. <i>Urology</i> , 2003, 61, 664-670.	0.5	60
137	Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat. <i>Urology</i> , 2003, 61, 656-663.	0.5	86
138	Botulinum toxin treatment of urethral and bladder dysfunction. <i>Journal of the Formosan Medical Association</i> , 2003, 102, 5-11.	0.8	13
139	THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTOR. <i>Journal of Urology</i> , 2001, 165, 975-979.	0.2	138
140	Autologous Primary Muscle-Derived Cells Transfer into the Lower Urinary Tract. <i>Tissue Engineering</i> , 2001, 7, 395-404.	4.9	58